Maher Masoud, President and CEO of MaxCyte, Inc., filed a Form 4 on November 18, 2026, disclosing an open-market purchase of 100,000 shares of MaxCyte common stock on November 17, 2026.
Key Highlights
- Reporting Person: Masoud Maher, President and CEO and Director of MaxCyte, Inc.
- Transaction: Purchase (Code P) of 100,000 shares of common stock on November 17, 2026.
- Weighted Average Price: $1.2078 per share, with individual transactions ranging from $1.185 to $1.21, inclusive.
- Resulting Ownership: 575,000 shares of common stock beneficially owned directly following the transaction.
- Exchange and Ticker: NASDAQ:MXCT
MaxCyte President and CEO Purchases 100,000 Common Shares on November 17, 2026
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Masoud Maher, who serves as both President and CEO and as a Director of MaxCyte, Inc. (NASDAQ:MXCT), acquired 100,000 shares of the company's common stock. The transaction is coded "P," indicating an open-market purchase, and was executed on November 17, 2026.
The filing reports a weighted average purchase price of $1.2078 per share. As disclosed in the footnotes, the shares were acquired in multiple transactions at prices ranging from $1.185 to $1.21, inclusive. The filing states that Masoud Maher "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
Following the reported transaction, the filing indicates that Masoud Maher directly beneficially owns 575,000 shares of MaxCyte common stock. No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and is not indicated as an amendment to a prior filing.
What Was Disclosed
The filing disclosed a direct open-market purchase of 100,000 shares of MaxCyte common stock by the company's President and CEO on November 17, 2026, at a weighted average price of $1.2078, resulting in direct beneficial ownership of 575,000 shares.



Please wait processing your request...